| 18th week of 2011 patent applcation highlights part 58 |
| Patent application number | Title | Published |
|---|
| 20110105382 | CALMODULIN-BINDING PEPTIDES THAT REDUCE CELL PROLIFERATION IN CANCER AND SMOOTH MUSCLE PROLIFERATION DISEASES - The invention relates to an isolated peptide comprising all or part of the amino acid sequence: GGAEFSARSR KRKANVTVFL QD (SEQ ID NO: 2), wherein the peptide reduces cell proliferation. The invention also includes variants, such as SEQ ID NO:3-5 and fragments of at least 5 amino acids of SEQ ID NO:2-5 that reduce cell proliferation. The peptides are useful for treating cancer and diseases characterized by smooth muscle proliferation, such as restenosis. | 2011-05-05 |
| 20110105383 | METHODS AND COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR polypeptide or peptide or fragment or derivative or analog thereof to the individual. | 2011-05-05 |
| 20110105384 | USE OF POLYPEPTIDES HAVING ANTIMICROBIAL ACTIVITY - The present invention relates to the use of polypeptides related to a | 2011-05-05 |
| 20110105385 | Antibacterial lactobacillus GG peptides and methods of use - The present invention provides antibacterial peptides isolated from | 2011-05-05 |
| 20110105386 | USE OF ANTIMICROBIAL POLYMERS FOR RE-SENSITIZATION OF MICROORGANISMS UPON EMERGENCE OF RESISTANCE TO ANTI-MICROBIAL AGENTS - Methods and compositions for treating microbial infections associated with an emergence of resistance of a pathogenic microorganism to an antimicrobial agent, following treatment with antimicrobial agent are disclosed. The methods are effected by using a polymer which exhibits antimicrobial re-sensitizing activity, for re-sensitizing the pathogenic microorganisms to the antimicrobial agent, in combination with the antimicrobial agent. Further disclosed are novel polymers having an antimicrobial re-sensitizing activity. | 2011-05-05 |
| 20110105387 | Method of treatment with rapamycin - The invention comprises a method of treatment using an oral capsule dose of rapamycin formulated with PEG-lipids. Two types of PEG-lipids are used in the formulation. A solubilizing agent dissolves the rapamycin, and solidifying agent is used to convert the solution of rapamycin/solubilizing agent to a more solid form. | 2011-05-05 |
| 20110105388 | NOVEL POSSIBILITY OF CONTROLLING GIARDIOSIS - The present invention relates to the use of nifurtimox for the treatment of giardiosis, in particular in dogs and cats. | 2011-05-05 |
| 20110105389 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders. | 2011-05-05 |
| 20110105390 | SELECTION AND TREATMENT OF PATIENTS SUFFERING FROM WASTING - The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions. | 2011-05-05 |
| 20110105391 | Methods and Compositions for Delivering Peptides - Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery. | 2011-05-05 |
| 20110105392 | Pegylated Insulin Lispro Compounds - The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses. | 2011-05-05 |
| 20110105393 | METHODS FOR PROMOTING STEM CELL PROLIFERATION AND SURVIVAL - Methods are disclosed herein for increasing the number of stem cells or precursor cells. The number of stem cells can be increased by increasing survival and/or cell proliferation of the cells. The methods include contacting the cells with an effective amount of a Notch ligand, an effective amount of a growth factor, and an effective amount of angiopoietin-2 (Ang-2). In several embodiments, the methods include contacting the cells with an effective amount of a Jak inhibitor. In several non-limiting examples, the growth factor is insulin or glial derived neurotrophic factor (GDNF), or a combination thereof. In additional non-limiting examples, the Notch ligand is Delta. The cells can be in vivo or in vitro. Methods are also disclosed here for the treatment of a neurodegenerative disorder or spinal cord injury in a subject. In several non-limiting examples, the subject has Parkinson's disease or Alzheimer's disease. | 2011-05-05 |
| 20110105394 | Amylin Derivatives - The present invention relates to novel amylin derivatives, pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the amylin derivatives of the invention. | 2011-05-05 |
| 20110105395 | METHODS FOR TREATING A NEUROLOGICAL DISORDER BY PERIPHERAL ADMINISTRATION OF A TROPHIC FACTOR - The invention provides methods of treating a subject having a disease, disorder or condition of the central nervous system. The methods include administering TGF-α polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating progenitor cell or stem cell proliferation, migration and differentiation. The methods of the invention are useful to treat and prophylactically ameliorate neurological tissue injury in vivo. | 2011-05-05 |
| 20110105396 | TGF-BETA3 MUTANTS - The invention provides TGF-β3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-β3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-β3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-β3 is replaced with Proline. Further still, the invention provides TGF-β3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-β3 and/or the Arginine residue at position (52) of full-length wild type TGF-β3. The invention also provides medicaments and methods of treatment using such TGF-β3s. | 2011-05-05 |
| 20110105397 | METHOD FOR TREATING HEART FAILURE WITH STRESSCOPIN-LIKE PEPTIDES - The present invention relates to novel methods of treating heart failure comprising administering an amount of stresscopin-like peptide to a subject in need thereof; and substantially maintaining the amount of said peptide present in the plasma of said subject at a concentration resulting in a therapeutic benefit without a substantial increase in the heart rate of said subject. The method involves the use of stresscopin-like peptides that are selective corticotrophin releasing hormone receptor type 2 (CRHR2) agonists. | 2011-05-05 |
| 20110105398 | RECOMBINANT FSH INCLUDING ALPHA 2,3- AND ALPHA 2,6-SAILYLATIO - Preparations including recombinant FSH (rFSH). | 2011-05-05 |
| 20110105399 | PREVENTION AND TREATMENT OF INFLAMMATION AND ORGAN INJURY AFTER ISCHEMIA/REPERFUSION USING MFG-E8 - Provided are methods for preventing and treating inflammation and organ injury after ischemia/reperfusion, and methods for treating lung injury, comprising administering a milk fat globule epidermal growth factor-factor VIII (MFG-E8) to a subject. Also provided are pharmaceutical compositions comprising MFG-E8 in dosage form for preventing and treating inflammation and organ injury after ischemia/reperfusion, and for treating lung injury, and methods of preparing a pharmaceutical composition for preventing and treating inflammation and organ injury after ischemia/reperfusion, and for treating lung injury, comprising formulating MFG-E8 in a pharmaceutical composition. | 2011-05-05 |
| 20110105400 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTION - The present invention includes methods of treating acute myocardial infarction in a subject, comprising administering to the subject a therapeutically effective amount of a non-proteolytically activated thrombin receptor agonist. | 2011-05-05 |
| 20110105401 | PEPTIDE COMPOSITION AND A METHOD OF PROMOTING CARTILAGE FORMATION - The present invention is a peptide compound which stimulates the formation of hard tissues such as bone and cartilage. The invention is also related to a method to treat a defect in hard tissues such as bone and cartilage using the peptide. The method of the present invention may be used to treat or prevent the defects in bones and cartilages which are caused by rheumatoid arthritis or osteoarthritis which involves the regeneration of new bone or cartilage in or around the defects. | 2011-05-05 |
| 20110105402 | Silk Peptide For Improving Neuroprotective And Neurofunctional Effects And A Method Of Its Prepartion - A silk peptide having neuroprotective and neurofunctional activities and its preparation method are discussed. One method relates to preparing silk protein preferably having neuroprotective activity with weight average molecular weight of 200-100,000 by hydrolysis of silk fibroin; also discussed are a composition for preventing or treating brain disease comprising silk peptide and pharmaceutically acceptable carrier, and a composition for improving brain function. | 2011-05-05 |
| 20110105403 | PEPTIDES - The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule. | 2011-05-05 |
| 20110105404 | Beta Sheet Inhibiting Peptides For Preventing And/Or Treating Alzheimer`s Disease - Provided are β-sheet breaker peptides binding to β amyloid peptide (Aβ1-42), which have the homologous sequence with Aβ 14-23. β-sheet breaker peptides can be used for the manufacture of a medicament for prophylactic and/or therapeutic treatment of Alzheimer's Disease. | 2011-05-05 |
| 20110105405 | METHOD FOR ALLEVIATING PAIN USING PROTEIN ASSOCIATED WITH MYC AND RELATED COMPOUNDS, AND ASSAYS FOR IDENTIFYING SUCH COMPOUNDS - Use of PAM or functional fragments or derivatives thereof for the preparation of pharmaceutical compounds. | 2011-05-05 |
| 20110105406 | Transparent Cosmetic Compositions - The present invention relates to a cosmetic composition comprising: a) from about 0.05% to about 10% of a salt form active; b) from about 0.001% to about 2% of a thickening agent; and c) water, wherein the composition has a turbidity no higher than about 10 NTU, and has a pH in the range of about 5.0 to about 6.8. | 2011-05-05 |
| 20110105407 | Tissue Inhibitor of Metalloproteinases (Timp) Linked to Glycosylphosphatidylinositol (Gpi) - Anchors for Treatment of Cancer and Skin Lesions - The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced apoptosis. Furthermore, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, the TIMP is linked to mucin followed by GPI in order to enhance surface presentation. The use of GPI to link TIMP renders the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer following an incomplete surgical resection of primary tumors in an individual. | 2011-05-05 |
| 20110105408 | THERAPEUTIC PEPTIDES - The invention relates to dendrimer agents presenting polypetides providing the binding domain of a β integrin sub-unit for an ERK MAP kinase, or a variant or modified form of the binding domain, and the use of the dendrimers to inhibit growth of cancer cells. The peptides present more that 8 units of the polypeptide(s) examples of which include the peptide RSKAKNPLYR (SEQ ID No. 6). | 2011-05-05 |
| 20110105409 | Anticancer Compounds - Anticancer compounds of general formula I: | 2011-05-05 |
| 20110105410 | Beta-Turn Peptidomimetic Cyclic Compounds for Treating Dry Eye - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 2011-05-05 |
| 20110105411 | Disease-Associated Proteins - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions. | 2011-05-05 |
| 20110105412 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS - This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS. | 2011-05-05 |
| 20110105413 | POLYMERIC SYSTEMS CONTAINING INTRACELLULAR RELEASABLE DISULFIDE LINKER FOR THE DELIVERY OF OLIGONUCLEOTIDES - The present invention provides polymeric prodrugs including an intracellular releasable disulfide linker for the delivery of oligonucleotides. Methods of making the compounds as well as methods of delivering nucleic acids to tumor cells in a mammal using the same are also provided. | 2011-05-05 |
| 20110105414 | CYCLIC, CYSTEIN-FREE PROTEIN - A protein selected from the amino acid sequence of the region valine Val(91) to glycine Gly(l21) of the mature human tumour necrosis factor, or a portion thereof, with the proviso that the protein comprises at least the amino acid sequence of the region lysine Lys(98) to glutamic acid Glu(116), with the cysteine Cys(101) being replaced by a glycine and an amide bond being formed between the amino group of the side chain of the lysine Lys(98) and the carboxyl group of the side chain of the glutamic acid Glu(116), which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas. | 2011-05-05 |
| 20110105415 | Gene regulator - The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of a variety of diseases. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signalling molecule comprising a peptide or functional analogue thereof. Furthermore, the invention provides a method for identifying or obtaining a signalling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing the cell with a peptide or derivative or analogue thereof and determining the activity and/or nuclear translocation of a gene transcription factor. | 2011-05-05 |
| 20110105416 | Novel Antimicrobial Peptides - The present invention relates to a peptide of linear, non-cyclic structure consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11) W, L or F; (12) K or R; (13) F, Y or C; (14) K or R; (15) G or Q; (16) K or R; (17) F, L or W; (18) F or W; (19) F, L or W; (20) W or F; (21) C or lacking; (22) F or G or lacking (23) G or lacking. Further, the invention relates to a nucleic acid molecule encoding the peptide of the invention, an expression vector comprising the nucleic acid molecule of the invention, a host cell which may be grown in cell culture comprising the vector of the invention, and a method of producing the peptide of the invention comprising culturing the host cell of the invention and collecting the peptide produced. Also, the present invention relates to a pharmaceutical composition comprising the peptide of the invention, the peptide produced by the method of the invention, the nucleic acid molecule of the invention, the expression vector of the invention or the host cell of the invention and a kit comprising the peptide of the invention, the peptide produced by the method of the invention, the nucleic acid molecule of the invention, the expression vector of the invention or the host cell of the invention. | 2011-05-05 |
| 20110105417 | Drug Conjugates - Conjugated compounds comprising a therapeutic or diagnostic agent linked to a substrate for a cell membrane transporter or receptor by lipophilic linker are provided. | 2011-05-05 |
| 20110105418 | PROCESS FOR PREPARING FONDAPARINUX SODIUM AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF - Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions. | 2011-05-05 |
| 20110105419 | PHARMACOLOGICAL ADJUVANTS BASED ON COORDINATION COMPOUNDS OF D-METALS - The invention relates to the use of small and ultra small quantities of bi- and oligo-nuclear forms of the coordination compounds of d-metals in the form of drugs or agents for enhancing the therapeutic efficiency of pharmacological substances. | 2011-05-05 |
| 20110105420 | AMINOSUGAR COMPOUND AND PROCESS FOR PRODUCTION THEREOF - [Object] Disclosed is a compound useful as an active ingredient for a pharmaceutical composition having an α-amylase inhibitory activity, particularly a pharmaceutical composition for the treatment of diabetes. | 2011-05-05 |
| 20110105421 | ELLAGITANNINS AS INHIBITORS OF BACTERIAL QUORUM SENSING - Described herein are materials and methods for the inhibition of bacterial QS. Methods of treating bacterial infections by administration of one or more ellagitannins in amount effective to inhibit bacterial QS is also provided. | 2011-05-05 |
| 20110105422 | USE OF G-RICH OLIGONUCLEOTIDES FOR TREATING NEOPLASTIC DISEASES - The invention relates to methods of treating patients (either adult or paediatric) with tumours using G rich oligonucleotides. In embodiments of the invention, methods of treating patients with tumours using a combination of G rich oligonucleotides and a chemotherapeutic agent are provided. There are also provided pharmaceutical compositions and kits for use in the methods of the invention. | 2011-05-05 |
| 20110105423 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF - The present invention relates to compounds that modulate the replication of negative-sense, single-stranded RNA viruses, such as influenza virus, and the use of such compounds. The invention relates to methods for increasing the titer of negative-sense, single-stranded RNA viruses, such as influenza virus, in substrates for virus propagation (e.g., tissue culture). The invention also relates to the use of compounds that decrease virus replication as antiviral agents. The invention further relates to methods for identifying compounds that modulate the replication of negative-sense, single-stranded RNA viruses, in particular, influenza virus. | 2011-05-05 |
| 20110105424 | GLUCOPYRANOSIDE COMPOUND - A compound of the formula: | 2011-05-05 |
| 20110105425 | USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER - The present invention relates to the novel use of an adenosine aspartate product for the formulation of a drug intended to prevent the development of preneoplastic lesions and to reverse some types of cancer, particularly liver cancer, providing chemoprotection, preventing myelotoxic effects. | 2011-05-05 |
| 20110105426 | COMPOSITIONS AND METHODS FOR TREATING CORNEAL INFLAMMATION - A method of treating corneal inflammation in a subject includes administering to the subject a therapeutically effective amount of a TLR4 antagonist. | 2011-05-05 |
| 20110105427 | DEAZAPURINES AND USES THEREOF - The present invention provides compounds having formula (I): | 2011-05-05 |
| 20110105428 | HYDROLYSIS RESISTANT ORGANOMODIFIED SILYLATED IONIC SURFACTANTS - The present invention provides for a composition comprising a silane having the formula: | 2011-05-05 |
| 20110105429 | Thiazole-4-Carboxylic Acid Esters and Thioesters as Plant Protection Agents - The use of thiazole-4-carboxylic esters and thioesters of the formula (I) | 2011-05-05 |
| 20110105430 | PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS - Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (A) are inhibitors N of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation. | 2011-05-05 |
| 20110105431 | Boronic Acid Aryl Analogs - The present invention relates to novel boronic acid aryl derivatives which are useful as antitumor/anticancer agents. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good inhibitors of the growth of human breast cancer cells. The present invention also relates to the use of the novel boronic acid aryl derivatives to treat cancer. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of cancer. | 2011-05-05 |
| 20110105432 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF - The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. | 2011-05-05 |
| 20110105433 | LECITHIN AND LC-PUFA - The present invention relates generally to the prevention/and or stopping of the generation of off-flavours in food products. In particular is the present invention directed to the formulation of lipid raw material mixes and food products containing long chain polyunsaturated fatty acids, and to compositions and processes for stabilizing such products against the formation of off-flavours, such as fishy off-odours. One embodiment of the present invention is a composition comprising an LC-PUFA containing oil and lecithin, wherein weight ratio of lecithin to LC-PUFA is at least about 25:75. | 2011-05-05 |
| 20110105434 | 2-AMINO PURINE DERIVATIVES AND THEIR USE AS ANTI-HERPETIC AGENTS - Anti-herpetic material such as 2-amino purine derivatives to prevent or treat autoimmune disease or a disease originating from an abnormal functioning of the sympathetic chain in a human subject. The disease is often of a tissue or organ associated with decreased blood flow to the tissue or organ (correlated with hypertonicity of the vessels feeding the tissue or organ). The treatment reduces inflammation, scarring, destruction, and pain in the tissue or organ affected and returns the tissue or organ to nearly normal functioning, while showing none of the side effects of previous treatments. Prolonged use of the anti-herpetic compounds reduces prodrome, vesicle formation and viral shedding. The anti-herpetic compounds may be administered alone or in combination with a compound that reduces the rate of renal excretion of the anti-herpetic compound. The anti-herpetic compounds are particularly useful when administered at a level equivalent in activity to 250 mg/kg famciclovir per day. | 2011-05-05 |
| 20110105435 | THERAPY OPTION FOR RECOLORATION OF HAIR VIA BISPHOSPHONATES BY PHYSIOLOGICAL REPIGMENTATION WITH AGE-RELATED AND/OR PREMATURE "GRAYED" PATIENTS - The present invention relates to the use of a bisphosphonate derivative according to general Formula I | 2011-05-05 |
| 20110105436 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT - Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent. | 2011-05-05 |
| 20110105437 | Mitochondrially Delivered Anti-Cancer Compounds - This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant vitamin E analogue, such as α-tocopheryl succinate, α-tocopheryl maleate, α-tocopheryl maleyl amide, or 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (α-tocopheryloxyacetic acid). | 2011-05-05 |
| 20110105438 | Oligomer-Foscarnet Conjugates - The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds. | 2011-05-05 |
| 20110105439 | Ceramide Production Promoter - Provided are a drug, a cosmetic, etc. for promoting production of ceramide. | 2011-05-05 |
| 20110105440 | HEXAHYDROCYCLOPENTYL[f]INDAZOLE SULFONAMIDES AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS - The present invention is directed to hexahydrocyclopentylf]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included. | 2011-05-05 |
| 20110105441 | Stable Orally Disintegrating Tablets Having Low Superdisintegrant - The invention is directed to the functionality and performance of superdisintegrants in orally disintegrating tablets (ODT). The invention can be an aged direct compression ODT having between about 0.3% to about 2% (wt/wt) sodium croscarmellose relative to the total weight of the ODT, a polyol matrix, optionally a lubricant, and an active pharmaceutical or nutraceutical ingredient, in which after storage for four months the ODT has a disintegration time using an excess water test that is less than 30 seconds and a tensile strength greater than 0.5 MPa. The invention is also directed to a direct compression ODT, consisting essentially of about 0.5% to 2.0% sodium croscarmellose, from 0.1% to 2.0% lubricant, an API, up to 10% (wt/wt) microcrystalline cellulose, optionally one or more colorants, sweeteners, fragrances, flavor compounds, and/or flavor blockers, and the balance spray-dried mannitol. | 2011-05-05 |
| 20110105442 | MEANS AND METHODS FOR CONTROLLING COMMENSALES -
The present invention relates to a cosmetic composition for the cleaning of the skin, said composition comprising or consisting of one or more compounds of formula (I)
| 2011-05-05 |
| 20110105443 | SALTS OF MEMANTINE AND COX-INHIBITORS AND THEIR CRYSTAL FORM IN THE TREATMENT OF PAIN - The present invention relates to salts of Memantine and COX-INHIBITORs, their crystal form, the processes for preparation of the same and their uses for the treatment of various disorders, including pain. | 2011-05-05 |
| 20110105444 | ONCE-A-WEEK ADMINISTRATION OF 25-HYDROXY VITAMIN D3 TO SUSTAIN ELEVATED STEADY-STATE PHARMACOKINETIC BLOOD CONCENTRATION - An oral dosage form comprising a single dose of 25-hydroxy-vitamin D | 2011-05-05 |
| 20110105445 | ANDROGEN RECEPTOR INACTIVATION CONTRIBUTES TO ANTITUMOR EFFICACY OF CYP17 INHIBITORS IN PROSTATE CANCER - Provided are methods of inhibiting CYP17 in a mammal, such as a human, that include administering an effective amount of at least one CYP17 inhibitor, such as VN/124-1, VN/125-1, VN/85-1, VN/87-1 and/or VN/108-1 to the mammal. Also provided are methods of down regulating androgen receptor (AR) protein expression and methods of antagonizing AR in a mammal that include administering to the mammal an effective amount of at least one active ingredient selected from VN/124-1, VN/125-1, VN/85-1, VN/87-1 and VN/108-1. Also provided are methods of treating prostate cancer and methods of suppressing or preventing prostate tumor growth by administering such compounds to a mammal. | 2011-05-05 |
| 20110105446 | Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment - Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally. | 2011-05-05 |
| 20110105447 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL - Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer. | 2011-05-05 |
| 20110105448 | Stable Topical Formulation Comprising Voriconazole - The present invention relates to a stable topical formulation comprising an effective amount of voriconazole or its pharmaceutically acceptable salt, and at least a pharmaceutical carrier; a process for preparing the same and use of such formulation for the treatment of local or non-systemic fungal infections in a subject. In particular, the present invention relates to a stable topical formulation exhibiting a storage stability at a temperature of about 40° C. and a relative humidity of about 75% for a period of at least 3 months, and contains not more than 9% w/w total impurities (based on total weight of the formulation) formed upon storage. | 2011-05-05 |
| 20110105449 | DRY POWDER FORMULATIONS COMPRISING ASCORBIC ACID DERIVATES - The invention provides dry powder pharmaceutical formulations comprising an ascorbic acid derivative that demonstrate good inhalation performance and dry powder inhalers containing them. | 2011-05-05 |
| 20110105450 | OPHTHALMIC FORMULATIONS OF FLUTICASONE AND METHODS OF USE - The present invention provides ophthalmic formulations of fluticasone that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic conjunctivitis in a subject in need of such treatment by topical application of the fluticasone formulations of the invention directly to the eye. | 2011-05-05 |
| 20110105451 | Screening of a Novel Hepatic Syndrome and its Uses - The invention concerns methods of screening for a hepatic syndrome occurring in the young adult and associating cholesterol biliary microlithiasis, intrahepatic cholestasis and several mutations of the MDR3 gene. The invention is also directed to methods for the treatment of said syndrome. The hepatic syndrome screening methods comprise detecting, from a nucleic acid sample extracted from peripheral blood mononucleate cells, heterozygous mutations of the MDR3 gene and/or homozygous mutations of the MDR3 gene that do not eliminate the expression of the protein expressed by the MDR3 gene, which has phosphatidylcholine carrier activity, in adult subjects associating cholesterol biliary microlithiasis and intrahepatic cholestasis. | 2011-05-05 |
| 20110105452 | Oxidant Scavengers for Treatment of Diabetes or Use in Transplantation or Induction of Immune Tolerance - The present invention relates, in one embodiment, to a method of preventing or treating diabetes using low molecular weight antioxidants. In a further embodiment, the invention relates to a method of protecting and/or enhancing viability of cells/tissues/organs during isolation (harvesting), preservation, expansion and/or transplantation. In yet another embodiment, the present invention relates to a method of inducing immune tolerance. The invention also relates to compounds and compositions suitable for use in such methods. | 2011-05-05 |
| 20110105453 | Superoxide Dismutase Mimics For The Treatment Of Optic Nerve And Retinal Damage - Methods for preventing and treating damage to the optic nerve and/or retina by the use of SOD mimics, particularly pentaazacycle Mn | 2011-05-05 |
| 20110105454 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES - The present invention relates to novel substituted oxindole derivatives of the formula (I), pharmaceutical agents containing said derivatives, and the use thereof for the treatment of vasopressin-dependent illnesses. | 2011-05-05 |
| 20110105456 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT | 2011-05-05 |
| 20110105457 | HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON PI3K - The purpose of the present invention is to provide a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prevention/treatment of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. This was achieved by providing a substituted 2-amino-5,6-nitrogenated fused ring compound shown in the present specification, or a pharmaceutically acceptable salt thereof. | 2011-05-05 |
| 20110105458 | FATTY ACID INHIBITORS - Fatty acid inhibitors, pharmaceutical compositions including fatty acid inhibitors, methods for using fatty acid inhibitors to treat a variety of diseases, and methods for preparing fatty acid inhibitors are provided herein. | 2011-05-05 |
| 20110105459 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS - The invention relates to compounds of formula (I) wherein R, R | 2011-05-05 |
| 20110105460 | TRIAZOLE DERIVATIVE OR SALT THEREOF - [Problem] A compound, which can be used for preventing or treating diseases, in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, in particular, diabetes, insulin resistance, dementia, schizophrenia and depression, is provided. | 2011-05-05 |
| 20110105461 | MODULATORS OF DOPAMINE NEUROTRANSMISSION - The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2011-05-05 |
| 20110105462 | MODULATORS OF DOPAMINE NEUROTRANSMISSION - The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2011-05-05 |
| 20110105463 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES - Compounds of Formula (I): in which A | 2011-05-05 |
| 20110105464 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2011-05-05 |
| 20110105466 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE - Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status. | 2011-05-05 |
| 20110105467 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE - Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status. | 2011-05-05 |
| 20110105468 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE - Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status. | 2011-05-05 |
| 20110105469 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE - Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status. | 2011-05-05 |
| 20110105470 | Novel Lapachone Compounds And Methods of Use Thereof - The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione). | 2011-05-05 |
| 20110105471 | NOVEL CRYSTALLINE COMPOUND AND A PROCESS FOR ITS PREPARATION - A form of crystalline (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide anhydrate Form II having improved flowability and drug-loading properties and a process for its preparation. | 2011-05-05 |
| 20110105472 | Diaminopyrimidines as crop protection agents - Use of diaminopyrimidines of the formula (I) | 2011-05-05 |
| 20110105473 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS - Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R | 2011-05-05 |
| 20110105474 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS - This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R | 2011-05-05 |
| 20110105475 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS - The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I). | 2011-05-05 |
| 20110105476 | SUBSTITUTED 7,8-DIHYDRO-1HPYRIMIDO[4,5-B]DIAZEPIN-4-AMINES ARE NOVEL KINASE INHIBITORS - Compounds having the Formula (I) | 2011-05-05 |
| 20110105477 | COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION - The present invention relates to HIV protease, and methods for inhibiting the function of HIV protease. In particular, present invention provides compounds that inhibit or block the biological activity of HIVp, thereby causing the replication of the HIV virus to be inhibited or to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS. The compounds and formulations also find use in diagnostic and research settings. | 2011-05-05 |
| 20110105478 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS - This invention relates to novel N-oxides of a 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivative and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2011-05-05 |
| 20110105479 | Inhibitors of Bruton's Tyrosine Kinase - This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: | 2011-05-05 |
| 20110105480 | PHARMACEUTICAL TRANSDERMAL COMPOSITIONS AND METHOD FOR TREATING INFLAMMATION IN CATTLE - Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) selected from groups such as oxicams (for example, meloxicam), propionic acids (for example, ketoprofen) and anthranilic acids (for example, tolfenamic acid), are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines are also disclosed. | 2011-05-05 |
| 20110105481 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC - A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within. | 2011-05-05 |
| 20110105482 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS - A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and αvβ | 2011-05-05 |
| 20110105483 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to the use of a substituted triazole compound of the invention, or a composition comprising such a compound in the preparation of a medicament for preventing or treating hyperprolif erative disorders, such as cancer, in a subject in need thereof. | 2011-05-05 |
